Capitolis Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Capitolis Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,247,287	Closed	-$413M	–	467
2021 Q2	$413M	Buy	2,247,287 +1,005,666	+81%	+$173M	4.85%	2
2021 Q1	$190M	Buy	1,241,621 +1,228,851	+9,623%	+$190M	3.28%	4
2020 Q4	$2M	Buy	+12,770	New	+$1.64M	0.03%	317

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Capitolis Advisors's ALXN Position: Q3 2021 in Review

Capitolis Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,247,287 shares — an estimated $413M sold.

Capitolis Advisors first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $413M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Capitolis Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Capitolis Advisors sold 2,247,287 Alexion Pharmaceuticals shares in Q3 2021, an estimated $413M.
Capitolis Advisors first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Capitolis Advisors's Alexion Pharmaceuticals position peaked at $413M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Capitolis Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.